Qian Chen

Dr. Qian Chen

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
WCWeie Cao
Weie Cao
QDQichen Ding
Qichen Ding
YWYijun Wang
Yijun Wang
SLShuyun Liu
Shuyun Liu
SSShixuan Sun
Shixuan Sun
YLYun Liu
Yun Liu

1 February 2021 in Clinical Therapeutics
Verified
Journal Article
Closed access
YZYi-Fan Zhang
Yi-Fan Zhang
YLYan-Mei Liu
Yan-Mei Liu
CYChen Yu
Chen Yu
YWYa-Ting Wang
Ya-Ting Wang
YZYan Zhan
Yan Zhan
DZDafang Zhong
Dafang Zhong

7 March 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
YLYun Liu
Yun Liu
WWWei Wang
Wei Wang
HQHongjie Qian
Hongjie Qian
YGYuzhou Gui
Yuzhou Gui
YWYating Wang
Yating Wang
JJJingying Jia
Jingying Jia
This study evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and food effects (FE) of SC0062, a highly active endothelin‐A (ETA) receptor antagonist, in healthy subjects. The primary objectives of this first‐in‐human phase I study, comprised of single‐ascending‐dose, multiple‐ascending‐dose, and FE parts, were to characterize the safety and tolerability of SC0062, and FE. The secondary objectives were to determine the PK behavior of SC0062 and its major active metabolite M18, whereas exploratory objectives focused on PD effects, principally effects on endothelin‐1 (ET‐1) and total bile acids (TBA). Single doses of 10 to 100 mg and multiple daily doses of 20 and 50 mg for 6 days were well tolerated. SC0062 was rapidly absorbed and plasma exposure of SC0062 and M18 increased disproportionately with dose, achieving steady state by day 3, with accumulation ratios of 1.22 and 1.89 on day 6 for SC0062 and M18, respectively. The geometric mean (geometric standard deviation) terminal elimination half‐life (t1/2) values of SC0062 and M18 were 7.25 (1.70) h and 13.73 (1.32) h, respectively. Plasma ET‐1 concentrations were dose‐proportional, whereas plasma TBA concentrations behaved erratically. Following a single 50 mg dose of SC0062 after a high‐fat meal, Cmax values for SC0062 and M18 increased by 41% and 32%, respectively, and median Tmax values for SC0062 were 3 h longer than fasting values; exposure was unaffected. These favorable safety, PK, and PD results provide a foundation for further studies of SC0062 in pulmonary arterial hypertension, chronic kidney disease, and other relevant indications.

22 May 2021 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
QDQichen Ding
Qichen Ding
MOMeixian Ou
Meixian Ou
HZHuijuan Zhu
Huijuan Zhu
YWYijun Wang
Yijun Wang
JJJingying Jia
Jingying Jia
JWJian Wang
Jian Wang

1 February 2019 in Clinical Therapeutics
Verified
Journal Article
Closed access
YLYan-Mei Liu
Yan-Mei Liu
PWPeggy Wu
Peggy Wu
RFRisa Fukushi
Risa Fukushi
SYShunsuke Yamada
Shunsuke Yamada
QCQian Chen
Qian Chen

1 December 2024 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
YZYang Zou
Yang Zou
FJFan Jiang
Fan Jiang
CSChan Sun
Chan Sun
CZChunyang Zhao
Chunyang Zhao
HQHongjie Qian
Hongjie Qian
QCQian Chen
Qian Chen